NIT Rourkela Innovation Advances Emergency Trauma Care with CDSCO-Approved StopBleed®
In its effort to bring innovations from the lab to the real world, National Institute of Technology Rourkela (NIT Rourkela), spined out Startup Miraqules MedSolutions Pvt. Ltd. has received regulatory approval for commercial manufacturing and clinical deployment of its patented technology, a rapid nano-biopolymer hemostat, to transform emergency hemorrhage control. The product has secured patent protection in India, USA, China, Australia, and Israel, demonstrating its global innovation and technological strength.
A major part of road accident fatalities occurs due to delays in patients’ bleeding control. Many of these incidents take place in remote or rural areas where trauma care is not readily available. The technology developed at NIT Rourkela can bridge this gap and reduce preventable casualties.
StopBleed®, the technology developed at NIT Rourkela, has received approval from the Central Drugs Standard Control Organisation (CDSCO) as a Class C medical device, marking a significant step in translating academic research into real-life-saving medical technology. The product facilitates rapid control of severe bleeding arising from military operations, road accidents, gunshot wounds, blast injuries, industrial accidents, deep stab wounds, and other critical or life-threatening trauma situations.
The developed innovation is an advanced bleeding control solution available in powder and pellet forms, designed to be used in trauma situations such as road accidents, military injuries, and emergency first-aid situations. With a shelf life of three years (at room temperature), it can be easily used by medical professionals and non-medical first-aid responders, making it suitable for emergency cases, which could lead to saving lives. Developed using nanofibrous aggregate technology, the product rapidly absorbs blood plasma while trapping blood cells within a high-surface-area fibrous mesh. This helps in accelerating the body’s natural clotting mechanisms and forms a strong hydrogel seal at the wound.
This technology was originally patented by the Institute and developed in the Department of Biotechnology and Medical Engineering by Professor Devendra Verma and his research graduate, Dr. Sabir Hossain. Subsequently, the technology was transferred to the startup Miraqules MedSolutions Pvt. Ltd., led by Dr. Hossain, for manufacturing, distribution, and field deployment.
In compliance with international safety standards (ISO 10993) and USFDA guidelines, team Miraqules has conducted multiple laboratory and animal testing of the developed innovation and found satisfactory results. It has also been tested in a real-life clinical setting through a first-in-human study conducted in collaboration with Sanjay Gandhi Institute of Trauma and Orthopedics, Bangalore.
